Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates

This will be a pivotal year for Theravance Biopharma Inc. due to multiple key data readouts for internally discovered molecules. The Dublin-headquartered firm talked to Scrip about its focus on organ-selective therapies as it looks ahead to data releases for symptomatic neurogenic orthostatic hypotension (NOH) and two inflammatory bowel disease indications.

In the spring of 2013, the then-Theravance Inc. detailed plans to divide into two companies. ([A#PSS075604]) One was R&D-focused Theravance Biopharma, which since has discovered and developed its own drug candidates while also advancing the pipeline via partnering while bringing in revenue through out-licensing. Meanwhile, the other was a royalty management company named Innoviva, Inc